---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014069"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:56:28.001872+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026

## Summary
- Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.
- Warrants include Series A (5-year, $1.22 strike) and Series B (2-year, $1.22 strike), 150% warrant coverage.
- Cash runway extended into 2026; combined with prior $6.1M Jan 2024 financing.
- Proceeds fund pivotal Phase III TIGeR-PaC trial through second interim readout (est. late 2024).
- Financing also enables expansion of TAMP clinical pipeline into additional cancer indications.

## SEC filing metadata
- accession: 0001493152-24-014069
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/0001493152-24-014069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014069
- JSON: https://secwatch.observer/filing/0001493152-24-014069.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014069.txt

## Key facts
- Material Agreements
  RenovoRx, Inc. entered into Subscription Agreements with approximately 170 accredited investors (effective 2024-04-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: approximately 170 accredited investors
  - Effective: 2024-04-04
  source text: On April 4, 2024, RenovoRx, Inc. (the “Company”) entered into a series of definitive subscription agreements (the “Subscription Agreements”) in connection with a private placement offering by the Company (the “Offering”) to approximately 170 accredited investors (the “Investors”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/0001493152-24-014069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.